|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM358173116 |
| 003 |
DE-627 |
| 005 |
20250104232825.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2023.109678
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1651.xml
|
| 035 |
|
|
|a (DE-627)NLM358173116
|
| 035 |
|
|
|a (NLM)37315680
|
| 035 |
|
|
|a (PII)S1521-6616(23)00441-2
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Chen, Jin Y
|e verfasserin
|4 aut
|
| 245 |
1 |
2 |
|a A nanobody-based complement inhibitor targeting complement component 2 reduces hemolysis in a complement humanized mouse model of autoimmune hemolytic anemia
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 26.07.2023
|
| 500 |
|
|
|a Date Revised 04.01.2025
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a C2 is an attractive therapeutic target for many complement-mediated diseases. We developed Nab1B10, a new anti-C2 nanobody that potently and selectively inhibits both the classical and lectin pathways of complement activation. Mechanistically, Nab1B10 binds to the C2a portion of C2 and inhibits the assembly of C3 convertase C4b2a. Nab1B10 cross-reacts with monkey but not rodent C2 and inhibits classical pathway-mediated hemolysis. Using a new complement humanized mouse model of autoimmune hemolytic anemia (AIHA), we demonstrated that Nab1B10 abolished classical pathway complement activation-mediated hemolysis in vivo. We also developed C2-neutralizing bi- and tetra-valent antibodies based on Nab1B10 and found these antibodies significantly more potent than the other anti-C2 monoclonal antibody that is already in clinical trials. These data suggest that these novel C2-neutralizing nanobodies could be further developed as new therapeutics for many complement-mediated diseases, in which pathogenesis is dependent on the classical and/or lectin pathway of complement activation
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a Research Support, N.I.H., Extramural
|
| 650 |
|
4 |
|a AIHA
|
| 650 |
|
4 |
|a C2
|
| 650 |
|
4 |
|a Classical pathway
|
| 650 |
|
4 |
|a Complement
|
| 650 |
|
4 |
|a Lectin pathway
|
| 650 |
|
4 |
|a Nanobody
|
| 650 |
|
7 |
|a Complement C2
|2 NLM
|
| 650 |
|
7 |
|a Complement Inactivating Agents
|2 NLM
|
| 700 |
1 |
|
|a Zhang, Lingjun
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Luo, Liping
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yang, Maojing
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Yinghua
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lin, Feng
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 253(2023) vom: 01. Aug., Seite 109678
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:253
|g year:2023
|g day:01
|g month:08
|g pages:109678
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2023.109678
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 253
|j 2023
|b 01
|c 08
|h 109678
|